联合化疗或大剂量白细胞介素 2 目前在黑色素瘤中是否有作用？

IF 2.6 4区医学 Q3 ONCOLOGY

Cancer journal Pub Date : 2024-03-01 DOI:10.1097/PPO.0000000000000703

Julie Fishman, Elizabeth I Buchbinder

{"title":"联合化疗或大剂量白细胞介素 2 目前在黑色素瘤中是否有作用？","authors":"Julie Fishman, Elizabeth I Buchbinder","doi":"10.1097/PPO.0000000000000703","DOIUrl":null,"url":null,"abstract":"Abstract: Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable responses to other treatments. Chemotherapy can work transiently in patients whose disease has progressed on immune checkpoint inhibitors and for whom there are no appropriate targeted therapy options. High-dose IL-2 therapy can still be effective for a very small number of patients following progression on other therapies. In addition, modified IL-2 agents and IL-2 in combination with tumor-infiltrating lymphocyte therapy may play a role in future treatments for melanoma.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?\",\"authors\":\"Julie Fishman, Elizabeth I Buchbinder\",\"doi\":\"10.1097/PPO.0000000000000703\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable responses to other treatments. Chemotherapy can work transiently in patients whose disease has progressed on immune checkpoint inhibitors and for whom there are no appropriate targeted therapy options. High-dose IL-2 therapy can still be effective for a very small number of patients following progression on other therapies. In addition, modified IL-2 agents and IL-2 in combination with tumor-infiltrating lymphocyte therapy may play a role in future treatments for melanoma.\",\"PeriodicalId\":9655,\"journal\":{\"name\":\"Cancer journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PPO.0000000000000703\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PPO.0000000000000703","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

摘要：免疫检查点抑制剂和靶向疗法彻底改变了黑色素瘤的治疗。然而，化疗和白细胞介素2（IL-2）疗法在对其他疗法没有持久反应的患者的后期治疗中可能仍有作用。对于使用免疫检查点抑制剂后病情恶化且没有合适的靶向治疗方案的患者，化疗可以起到短暂的作用。高剂量IL-2疗法对极少数接受其他疗法后病情进展的患者仍然有效。此外，改良的IL-2制剂和IL-2与肿瘤浸润淋巴细胞疗法的结合可能会在未来的黑色素瘤治疗中发挥作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?

Abstract: Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable responses to other treatments. Chemotherapy can work transiently in patients whose disease has progressed on immune checkpoint inhibitors and for whom there are no appropriate targeted therapy options. High-dose IL-2 therapy can still be effective for a very small number of patients following progression on other therapies. In addition, modified IL-2 agents and IL-2 in combination with tumor-infiltrating lymphocyte therapy may play a role in future treatments for melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer journal 医学-肿瘤学

CiteScore

3.90

自引率

0.00%

发文量

102

审稿时长

7.5 months

期刊介绍： The Cancer Journal: The Journal of Principles & Practice of Oncology provides an integrated view of modern oncology across all disciplines. The Journal publishes original research and reviews, and keeps readers current on content published in the book Cancer: Principles & Practice of Oncology.